Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
Abstract
Aggressive variant prostate cancer (AVPC) is a nonandrogen receptor–driven form of disease that arises in men in whom standard-of-care therapies have failed. Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately quantify patient response to therapy by imaging. Imaging modalities that accurately and sensitively detect the bone and visceral metastases associated with AVPC do not exist.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-1659
Entities
People
- Aaron M LeBeau
- Ilsa M. Coleman
- Joseph P. Gallant
- Mariya Shapovalova
- Paari Murugan
- Paige M. Glumac
- Peter S Nelson
- Scott M Dehm
- Shilpa Gupta
- Yingming Li
Organizations
- National Cancer Institute
- United States Department of Defense
- University of Minnesota